Vir Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference
VIRSAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14 at 3:45 p.m. PT in San Francisco, California. A live webcast of the presentation will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website and will be archived for 30 days. About Vir Biotechnology
Vir Biotechnology Announces AASLD The Liver Meeting® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profi
VIRSAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Week 48 endpoint analysis from the Company’s Phase 2 SOLSTICE trial for chronic hepatitis delta (CHD) demonstrated that participants receiving a monthly dose of the combination of tobevibart and elebsiran achieved robust and sustained rates of hepatitis delta virus (HDV) RNA target not detected (TND), including those participants with cirrhosis and high baseline HDV RNA. The combination also showed alanin
Vir Biotechnology to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
VIRSAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9 at 1:05 p.m. PT / 4:05 p.m. ET in New York, New York. A live webcast of the fireside chat will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website and will be archi
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results
VIRSAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the second quarter ended June 30, 2025. “We achieved several important milestones across our pipeline, reflecting our commitment to our mission of powering the immune system to transform lives,” said Marianne De Backer, Chief Executive Officer, Vir Biotechnology. “The initiation of our Phase 1 study of PRO-XTEN™ dual-masked VIR-5525 positions us to potentia
Vir Biotechnology Successfully Initiates all Trials in ECLIPSE Registrational Program for Chronic Hepatitis Delta
VIRSAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the enrollment of the first participant in ECLIPSE 3. All three trials in the Company’s registrational ECLIPSE program for chronic hepatitis delta (CHD) have now been initiated. ECLIPSE 3 is a Phase 2b trial designed to compare the combination of tobevibart and elebsiran to bulevirtide treatment in patients with CHD. ECLIPSE 3 will provide important supportive data to help establish access and reimbursement in
Needham Reiterates Buy on Vir Biotechnology, Maintains $14 Price Target
VIRNeedham Maintains Buy on Vir Biotechnology, Lowers Price Target to $14
VIRVir Biotechnology Reveals Preliminary 24-Week Post-End of Treatment Data For Tobevibart And Elebsiran Combinations In Chronic Hepatitis B From MARCH Study, Reiterates Cash Runway Guidance Into Mid-2027, Based On The Current Operating Plan
VIRVir Biotechnology Q1 EPS $(0.88), Inline, Sales $3.03M Miss $8.59M Estimate
VIREarnings Outlook For Vir Biotechnology
VIRVir Biotechnology To Present Clinical Data In Hepatitis Delta and B Programs At EASL Congress 2025
VIR5 Analysts Have This To Say About Vir Biotechnology
VIRGoldman Sachs Maintains Buy on Vir Biotechnology, Lowers Price Target to $21
VIRVir Biotechnology Enrolls First Patient In Phase 3 ECLIPSE Registrational Program For Chronic Hepatitis Delta
VIRBarclays Maintains Overweight on Vir Biotechnology, Raises Price Target to $31
VIR7 Analysts Have This To Say About Vir Biotechnology
VIRHC Wainwright & Co. Reiterates Buy on Vir Biotechnology, Maintains $110 Price Target
VIRNeedham Reiterates Buy on Vir Biotechnology, Maintains $19 Price Target
VIRVir Biotechnology Q4 GAAP EPS $(0.76) Beats $(0.87) Estimate, Sales $12.37M Beat $8.14M Estimate
VIRLeerink Partners Maintains Outperform on Vir Biotechnology, Raises Price Target to $20
VIRMorgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why
VIRVir Biotechnology's Phase 1 data highlights early promise for T-cell engagers targeting HER2-positive tumors and prostate cancer with manageable safety.
HC Wainwright & Co. Reiterates Buy on Vir Biotechnology, Maintains $110 Price Target
VIRMorgan Stanley Upgrades Vir Biotechnology to Overweight, Raises Price Target to $20
VIRJP Morgan Maintains Neutral on Vir Biotechnology, Raises Price Target to $14
VIRHC Wainwright & Co. Reiterates Buy on Vir Biotechnology, Maintains $110 Price Target
VIRNeedham Reiterates Buy on Vir Biotechnology, Maintains $19 Price Target
VIRReported Earlier, Vir Biotechnology Announces Phase 2 Data And Phase 3 Launch For Chronic Hepatitis Delta Treatment
VIREMA Issued Opinion For Vir Biotechnology's Application For Orphan Drug Designation For Tobevibart And Elebsiran In Chronic Hepatitis Delta
VIRWhat's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday?
VIRVir Biotechnology's Phase 2 study on hepatitis B treatments shows promising antigen loss rates, with up to 46% achieving seroclearance in key regimens.
Barclays Maintains Overweight on Vir Biotechnology, Lowers Price Target to $26
VIRHC Wainwright & Co. Reiterates Buy on Vir Biotechnology, Maintains $110 Price Target
VIRNeedham Reiterates Buy on Vir Biotechnology, Maintains $19 Price Target
VIRVir Biotechnology Q3 2024 Adj EPS $(1.56) Misses $(1.05) Estimate, Sales $2.40M Miss $5.51M Estimate
VIRVir Biotechnology's SOLSTICE Data To Be Featured At The European Association For The Study Of The Liver Congress 2024
VIRThis Hepatitis Stock Has 'Multiple Paths To Value Creation,' Expects To Double, Bullish Analyst Predicts
VIRSVB Leerink Initiates Coverage On Vir Biotechnology with Outperform Rating, Announces Price Target of $40
VIRMorgan Stanley Initiates Coverage On Vir Biotechnology with Underweight Rating, Announces Price Target of $15
VIREarnings Outlook For Vir Biotechnology
VIRVir Biotechnology (NASDAQ:VIR) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement.
Analysts estimate that Vir Biotechnology will report an earnings per share (EPS) of $3.78.
